Help Patients Get to Goal With Heart Failure Meds

January 2023

Questions will come up about the best way to titrate meds for heart failure with reduced ejection fraction (HFrEF).

Less than 1% of patients are on target-dose “triple therapy” with an ACEI, ARB, or Entresto (sacubitril/valsartan)...an evidence-based beta-blocker (carvedilol, etc)...and an aldosterone antagonist.

Even fewer get the latest guideline-recommended “quad therapy” for HFrEF...by adding an SGLT2 inhibitor (Farxiga, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote